US5534263A
(en)
|
1995-02-24 |
1996-07-09 |
Alza Corporation |
Active agent dosage form comprising a matrix and at least two insoluble bands
|
CA2173818A1
(fr)
*
|
1996-04-10 |
1997-10-11 |
Francois Chouinard |
Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
|
US5804165A
(en)
*
|
1996-07-24 |
1998-09-08 |
Arnold; Michael J. |
Antiplaque oral composition
|
DE19640062B4
(de)
*
|
1996-09-28 |
2006-04-27 |
Lts Lohmann Therapie-Systeme Ag |
Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
IT1294760B1
(it)
*
|
1997-09-03 |
1999-04-12 |
Jagotec Ag |
Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
|
IN186245B
(pm)
*
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
GB9724186D0
(en)
|
1997-11-14 |
1998-01-14 |
British Tech Group |
Low temperature coatings
|
JP2001526234A
(ja)
*
|
1997-12-22 |
2001-12-18 |
シェーリング コーポレイション |
経口投与が可能な固形リバビリン投薬の形態およびそれらの製造プロセス
|
BR9910947A
(pt)
*
|
1998-06-05 |
2001-03-06 |
Warner Lambert Co |
Estabilização de composições que contêm inibidores de ace utilizando óxido de magnésio
|
AU761281B2
(en)
*
|
1998-09-25 |
2003-05-29 |
Delsys Pharmaceutical Corporation |
Liquid pharmaceutical for oral delivery
|
AU772891B2
(en)
|
1998-12-11 |
2004-05-13 |
Nostrum Pharmaceuticals, Inc. |
Sustained release tablet containing hydrocolloid and cellulose ether
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
MY121470A
(en)
*
|
1999-05-03 |
2006-01-28 |
Ranbaxy Lab Ltd |
Stable solid pharmaceutical compositions containing enalapril maleate
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
FR2797185B1
(fr)
*
|
1999-08-06 |
2001-10-26 |
Galenix Dev |
Composition pharmaceutique flottante comprenant une phase active et une phase non active
|
US6500462B1
(en)
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
JP4565456B2
(ja)
*
|
1999-11-02 |
2010-10-20 |
塩野義製薬株式会社 |
着色顆粒の色素定着法
|
US6399101B1
(en)
|
2000-03-30 |
2002-06-04 |
Mova Pharmaceutical Corp. |
Stable thyroid hormone preparations and method of making same
|
AR030557A1
(es)
*
|
2000-04-14 |
2003-08-27 |
Jagotec Ag |
Una tableta en multicapa de liberacion controlada y metodo de tratamiento
|
US6955821B2
(en)
*
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US6881420B2
(en)
*
|
2000-06-23 |
2005-04-19 |
Teva Pharmaceutical Industries Ltd. |
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
|
US7674480B2
(en)
*
|
2000-06-23 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd. |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
IL153497A0
(en)
*
|
2000-06-23 |
2003-07-06 |
Teva Pharma |
Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
DE10031043A1
(de)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
US20060099245A1
(en)
*
|
2000-08-01 |
2006-05-11 |
Manoj Kumar |
Hydrodynamically balancing oral drug delivery system with biphasic release
|
BR0115585A
(pt)
|
2000-11-28 |
2005-12-13 |
Fmc Corp |
Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
AU2002221412B2
(en)
*
|
2000-12-05 |
2006-04-13 |
Alexander Macgregor |
Hydrostatic delivery system for controlled delivery of agent
|
KR100685945B1
(ko)
|
2000-12-29 |
2007-02-23 |
엘지.필립스 엘시디 주식회사 |
액정표시장치 및 그 제조방법
|
US8268333B2
(en)
*
|
2001-04-24 |
2012-09-18 |
Lintec Corporation |
Orally administered agent and an orally administered agent/supporting substrate complex
|
DE10120092B4
(de)
*
|
2001-04-25 |
2008-03-20 |
Lts Lohmann Therapie-Systeme Ag |
Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
|
IL159812A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
|
IL159813A0
(en)
*
|
2001-07-12 |
2004-06-20 |
Teva Pharma |
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
|
CA2409552A1
(en)
*
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US20030104052A1
(en)
*
|
2001-10-25 |
2003-06-05 |
Bret Berner |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
WO2003042136A2
(en)
*
|
2001-11-13 |
2003-05-22 |
Teva Pharmaceutical Industries, Ltd. |
Process for the production of l-dopa ethyl ester
|
US20030099699A1
(en)
*
|
2001-11-13 |
2003-05-29 |
Hanshew Dwight D. |
Storage stable thyroxine active drug formulations and methods for their production
|
US6645526B2
(en)
*
|
2001-11-13 |
2003-11-11 |
Mylan Pharmaceuticals, Inc. |
Storage stable thyroxine active drug formulations and methods for their production
|
AU2002340470A1
(en)
|
2001-11-13 |
2003-05-26 |
Teva Pharmaceutical Industries, Ltd. |
L-dopa ethyl ester salts and uses thereof
|
EP1455801B1
(de)
*
|
2001-12-21 |
2005-03-09 |
Biopartners GmbH |
Ribavirin-granulat zur herstellung von filmtabletten
|
KR20030056474A
(ko)
*
|
2001-12-28 |
2003-07-04 |
한국유나이티드제약 주식회사 |
카르비도파/레보도파 서방정의 조성물과 그의 제조방법
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US7008979B2
(en)
*
|
2002-04-30 |
2006-03-07 |
Hydromer, Inc. |
Coating composition for multiple hydrophilic applications
|
US20060013875A1
(en)
*
|
2002-05-29 |
2006-01-19 |
Impax Laboratories, Inc. |
Combination immediate release controlled release levodopa/carbidopa dosage forms
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
EP2422772A3
(en)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
TWI319713B
(en)
*
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
US20040091538A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Crystal Pollock-Dove |
Dosage form providing ascending release of liquid formulation
|
US8906413B2
(en)
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
TWI372066B
(en)
*
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
JP2005132803A
(ja)
*
|
2003-10-31 |
2005-05-26 |
Ono Pharmaceut Co Ltd |
胃内滞留固形剤
|
JP4800219B2
(ja)
*
|
2003-12-16 |
2011-10-26 |
レレバーレ エーユーエスティー. ピーティーワイ リミテッド |
方法および組成物
|
US20070196396A1
(en)
*
|
2004-02-11 |
2007-08-23 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
WO2005084703A1
(ja)
*
|
2004-03-09 |
2005-09-15 |
Nrl Pharma, Inc. |
徐放性の口腔用組成物
|
FR2874325B1
(fr)
*
|
2004-08-19 |
2006-10-20 |
Sanofi Synthelabo |
Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
|
WO2006044805A2
(en)
*
|
2004-10-15 |
2006-04-27 |
Supernus Pharmaceuticals, Inc. |
Less abusable pharmaceutical preparations
|
US20060141001A1
(en)
*
|
2004-11-19 |
2006-06-29 |
Finkelmeier Steven D |
Pharmaceutical product
|
US20060246003A1
(en)
*
|
2004-12-27 |
2006-11-02 |
Eisai Co. Ltd. |
Composition containing anti-dementia drug
|
US20060159753A1
(en)
*
|
2004-12-27 |
2006-07-20 |
Eisai Co. Ltd. |
Matrix type sustained-release preparation containing basic drug or salt thereof
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
MX2007007836A
(es)
*
|
2004-12-27 |
2007-08-20 |
Eisai R&D Man Co Ltd |
Metodo para estabilizar un farmaco anti-demencia.
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
US20070003621A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
AR055070A1
(es)
*
|
2005-06-29 |
2007-08-01 |
Panacea Biotec Ltd |
Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso
|
US8795723B2
(en)
*
|
2005-09-09 |
2014-08-05 |
Angelini Pharma Inc. |
Sustained drug release compositions
|
CA2616416A1
(en)
*
|
2005-09-09 |
2007-05-03 |
Labopharm, Inc. |
Trazodone composition for once a day adminisitiation
|
NL2000281C2
(nl)
|
2005-11-02 |
2007-08-07 |
Pfizer Prod Inc |
Vaste farmaceutische samenstellingen die pregabaline bevatten.
|
EP1945189A4
(en)
|
2005-11-03 |
2012-08-15 |
Sun Pharmaceutical Ind Ltd |
CONTROLLED RELEASE COATED TABLETS CHARACTERIZED BY PROLONGED GASTRIC RETENTION
|
WO2007056570A2
(en)
*
|
2005-11-07 |
2007-05-18 |
Teva Pharmaceutical Industries Ltd. |
Levodopa compositions
|
US7674396B2
(en)
*
|
2005-11-08 |
2010-03-09 |
Plensat Llc |
Method and system for treatment of eating disorders
|
US8691272B2
(en)
*
|
2005-12-30 |
2014-04-08 |
Intelgenx Corp. |
Multilayer tablet
|
KR100752417B1
(ko)
*
|
2006-02-14 |
2007-08-28 |
대원제약주식회사 |
안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
|
US9011930B2
(en)
*
|
2006-05-01 |
2015-04-21 |
Zycal Bioceuticals Healthcare Company, Inc. |
Nutritional supplement and use thereof
|
CN101484165A
(zh)
*
|
2006-05-03 |
2009-07-15 |
Cns生物有限公司 |
治疗炎性疼痛的方法与组合物
|
US20100297226A1
(en)
*
|
2006-06-01 |
2010-11-25 |
Dexcel Pharma Technologies Ltd. |
Multiple unit pharmaceutical formulation
|
NZ573757A
(en)
|
2006-06-19 |
2011-11-25 |
Alpharma Inc |
Coated multilayer oral dosage forms of naltrexone hydrochloride
|
US20080131492A1
(en)
*
|
2006-06-23 |
2008-06-05 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
CA2662123C
(en)
*
|
2006-08-30 |
2015-12-01 |
Jagotec Ag |
Controlled release oral dosage formulations comprising a core and one or more barrier layers
|
WO2008039186A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Plensat, Llc |
Method and system for treatment of eating disorders
|
CA2664641A1
(en)
*
|
2006-09-26 |
2008-04-10 |
Astellas Pharma, Inc. |
Controlled release dosage form of tacrolimus
|
WO2008039193A2
(en)
*
|
2006-09-26 |
2008-04-03 |
Plensat, Llc |
Method and system for treatment of eating disorders
|
EP1935411A1
(en)
|
2006-12-15 |
2008-06-25 |
Campina Nederland Holding B.V. |
Slow release excipient and its use
|
US20100316712A1
(en)
*
|
2006-12-22 |
2010-12-16 |
Combinatorx, Incorporated |
Pharmaceutical compositions for treatment of parkinson's disease and related disorders
|
US20090011018A1
(en)
*
|
2006-12-28 |
2009-01-08 |
Astellas Pharma Inc., |
Sustained release formulation for tacrolimus
|
AT505225A1
(de)
*
|
2007-04-26 |
2008-11-15 |
Sanochemia Pharmazeutika Ag |
0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
RU2011101459A
(ru)
*
|
2008-06-16 |
2012-07-27 |
Аппиан Лабс, Ллк (Us) |
Композиция и способ получения систем высвобождения для постоянного (нулевого порядка) высвобождения активных средств
|
ES2740360T3
(es)
*
|
2008-08-15 |
2020-02-05 |
Assertio Therapeutics Inc |
Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
|
BRPI0914080A2
(pt)
*
|
2008-10-08 |
2015-10-27 |
Bioplus Life Sciences Pvt Ltda |
"sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo"
|
US20100112054A1
(en)
*
|
2008-10-23 |
2010-05-06 |
Appian Labs, Llc |
Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
|
US20100233259A1
(en)
*
|
2008-12-12 |
2010-09-16 |
Pascal Grenier |
Dosage form of ropinirole
|
EP2210585A1
(en)
|
2009-01-16 |
2010-07-28 |
Exelgyn |
SPRM pharmaceutical compositions methods of treatment using them
|
US20100249423A1
(en)
*
|
2009-03-09 |
2010-09-30 |
Sanochemia Pharmazeutika Ag |
Tolperisone controlled release tablet
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
WO2011078993A1
(en)
|
2009-12-21 |
2011-06-30 |
Aptapharma, Inc. |
Functionally-coated multilayer tablets
|
US20120070465A1
(en)
|
2010-03-29 |
2012-03-22 |
Astellas Pharma Inc. |
Pharmaceutical composition for modified release
|
JP5459670B2
(ja)
*
|
2010-05-07 |
2014-04-02 |
塩野義製薬株式会社 |
着色顆粒の色素定着化剤
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
IN2012DE00193A
(pm)
|
2012-01-23 |
2015-06-12 |
Ranbaxy Lab Ltd |
|
US10166207B2
(en)
|
2013-06-05 |
2019-01-01 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
US10098845B2
(en)
|
2013-10-07 |
2018-10-16 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
BR112016028180A2
(pt)
|
2014-06-02 |
2017-08-22 |
Teva Pharma |
forma de dosagem gastrorretentiva expansível
|
GB201506755D0
(en)
|
2015-04-21 |
2015-06-03 |
Reckitt Benckiser Llc |
Novel pharmaceutical formulation
|
US9617230B2
(en)
|
2014-12-22 |
2017-04-11 |
Farmington Pharma Development |
Creatine prodrugs, compositions and methods of use thereof
|
WO2016115253A1
(en)
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Ofcolordo, A Body Corporate |
Insulin mimotopes and methods of using the same
|
US10583177B2
(en)
*
|
2015-02-09 |
2020-03-10 |
Entera Bio Ltd. |
Formulations for oral administration of active agents
|
WO2016174664A1
(en)
|
2015-04-29 |
2016-11-03 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
US11278506B2
(en)
|
2015-10-09 |
2022-03-22 |
Rb Health (Us) Llc |
Pharmaceutical formulation
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
EP3432877B1
(en)
|
2016-03-24 |
2023-01-11 |
ImmunoMolecular Therapeutics, Inc. |
D-alpha-methyldopa for treating autoimmune disease
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
CN116831977A
(zh)
|
2016-08-17 |
2023-10-03 |
安提拉生物有限公司 |
用于口服的活性剂的制剂
|
EP3547974B1
(en)
|
2016-12-02 |
2023-11-15 |
Clexio Biosciences Ltd. |
Gastric residence system
|
KR102039345B1
(ko)
*
|
2017-02-01 |
2019-11-01 |
지엘팜텍주식회사 |
프레가발린 함유 고팽윤성 서방성 삼중정제
|
CA3082184A1
(en)
|
2017-12-01 |
2019-06-06 |
Ultragenyx Pharmaceutical Inc. |
Creatine prodrugs, compositions and methods of use thereof
|
JP7296084B2
(ja)
|
2017-12-04 |
2023-06-22 |
クレキシオ バイオサイエンシーズ エルティーディー. |
長時間作用型胃滞留システム
|
EP3740189A1
(en)
|
2017-12-18 |
2020-11-25 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
US11666546B2
(en)
|
2017-12-18 |
2023-06-06 |
Tris Pharma, Inc |
GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
US11052060B2
(en)
|
2018-02-12 |
2021-07-06 |
The Regents Of The University Of Colorado, A Body Corporate |
Compounds and methods for treating autoimmunity
|
US11013707B2
(en)
|
2018-03-23 |
2021-05-25 |
The Regents Of The University Of Colorado, A Body Corporate |
Administration of oral methyldopa
|
CA3097594A1
(en)
*
|
2018-05-15 |
2019-11-21 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Pharmaceutical composition comprising small molecule egfr inhibitor and preparation method therefor
|
CN110214860A
(zh)
*
|
2019-07-10 |
2019-09-10 |
聂刘明 |
一种宠物饲料及其制备工艺
|
WO2022140448A1
(en)
|
2020-12-22 |
2022-06-30 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
US11986449B2
(en)
|
2020-12-22 |
2024-05-21 |
Amneal Pharmaceuticals Llc |
Levodopa dosing regimen
|
US12409163B2
(en)
|
2021-07-30 |
2025-09-09 |
Evecxia Therapeutics, Inc. |
Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
|
CN116801868A
(zh)
*
|
2021-07-30 |
2023-09-22 |
埃维西亚治疗公司 |
5-羟色氨酸胃滞留剂型
|
EP4392031A4
(en)
|
2021-10-14 |
2025-07-30 |
Evecxia Therapeutics Inc |
METHOD FOR OPTIMIZING 5-HYDROXYTRYPTAMINE FUNCTION IN THE BRAIN FOR THERAPEUTIC PURPOSES
|
WO2023214018A1
(en)
|
2022-05-06 |
2023-11-09 |
Galenix Innovations |
Gastro-retentive swellable sustained release composition
|